SUMMARY: The American Cancer Society estimates that in 2026, about 67,530 people will be diagnosed with pancreatic cancer and 52,940 people will die of the disease. Pancreatic Ductal AdenoCarcinoma (PDAC) remains one of the most lethal malignancies, with most cases diagnosed at advanced stages and few modifiable risk factors identified to date. Although pancreatic cancer accounts for only about 3% of all cancer diagnoses in the United States, it is responsible for a disproportionate number of cancer-related deaths due to its aggressive biology and the fact that most patients present with advanced disease. More than half of pancreatic cancers are diagnosed after metastasis has already occurred, and outcomes remain poor despite advances in systemic therapy.
Standard second-line chemotherapy options have historically provided limited benefit, with median Progression-Free Survival (PFS) of approximately 3 to 4 months and median Overall Survival (OS) of just 6 to 7 months. While targeted therapies have transformed treatment paradigms in several solid tumors, their impact in pancreatic cancer has been restricted to relatively uncommon molecular subgroups.
The Phase 3 RASolute-302 trial may represent a turning point. Presented during the Plenary Session of the 2026 ASCO Annual Meeting, the study demonstrated that Daraxonrasib (RMC-6236), a first-in-class oral RAS(ON) multiselective inhibitor, significantly improved survival outcomes compared with standard chemotherapy in patients with previously treated metastatic PDAC.
Targeting a Central Driver of Pancreatic Cancer
The rationale for Daraxonrasib is rooted in the biology of pancreatic cancer itself. Aberrant activation of the RAS signaling pathway is recognized as the dominant molecular driver of PDAC, with oncogenic KRAS mutations identified in more than 90% of tumors. The majority of these alterations occur at codon 12, resulting in constitutive activation of the RAS protein and persistent downstream signaling through pathways that promote tumor growth and survival.
Although several KRAS-directed therapies have emerged in recent years, most are mutation-specific and target only a narrow subset of KRAS alterations. Daraxonrasib was designed to overcome this limitation through a broader mechanism of action.
Rather than binding directly to RAS, Daraxonrasib forms a complex with cyclophilin A that selectively engages the active GTP-bound form of RAS (active “ON” state) and suppresses downstream RAF signaling. This unique approach enables activity across multiple oncogenic RAS variants, including G12, G13, and Q61 mutations, as well as wild-type RAS. The agent also demonstrates activity across all three RAS isoforms: KRAS, NRAS, and HRAS.
This broad-spectrum activity has generated significant interest, particularly in PDAC, where dependence on RAS signaling extends beyond specific mutation subtypes and may also occur through pathway amplification or alterations elsewhere within the RAS-MAPK signaling cascade.
RASolute-302: Evaluating a New Therapeutic Strategy
RASolute-302 was a global, randomized, open-label Phase 3 trial conducted across 59 centers in North America, Europe, and Asia. The study enrolled 500 patients with previously treated metastatic PDAC and ECOG performance status 0–1. Eligible patients had received prior Fluoropyrimidine- or Gemcitabine-based therapy in the metastatic setting and were randomized 1:1 to receive either once-daily oral Daraxonrasib at 300 mg (N=248) or investigator’s choice of standard cytotoxic chemotherapy (N=252).
The trial employed dual Primary endpoints of Overall Survival and Progression-Free Survival in patients harboring RAS G12 mutations, who represented approximately 92% of the study population. Key Secondary endpoints included OS, PFS, objective response rate (ORR), and patient-reported outcomes in both the RAS G12 subgroup and the overall study population. Baseline characteristics were well balanced between treatment arms, allowing for a robust assessment of efficacy and safety.
Survival Outcomes Exceed Historical Expectations
At a median follow-up of 8.5 months, Daraxonrasib met all Primary and key Secondary endpoints, delivering results that substantially exceeded historical benchmarks for second-line treatment in metastatic pancreatic cancer.
Among patients with RAS G12-mutated disease, median Overall Survival reached 13.2 months with Daraxonrasib compared with 6.6 months for chemotherapy (HR=0.40; P<0.0001), translating into a 60% reduction in the risk of death. Progression-free survival similarly improved from 3.5 months with chemotherapy to 7.3 months with Daraxonrasib (HR=0.45; P<0.0001).
Importantly, the survival benefit extended beyond the primary analysis population. In the overall study cohort, including patients with RAS G13 mutations, RAS Q61 mutations, and those without identifiable RAS mutations, median OS remained 13.2 months with Daraxonrasib versus 6.7 months with chemotherapy (HR=0.40; P<0.0001). Median PFS was 7.2 months compared with 3.6 months, respectively (HR=0.49; P<0.0001).
These findings suggest that sustained inhibition of active RAS signaling may provide clinical benefit across a broader spectrum of pancreatic tumors than previously anticipated.
Lead investigator Brian Wolpin, MD, MPH, noted that the study addresses a major unmet need in metastatic PDAC, where no universally accepted second-line standard of care exists and available chemotherapy regimens offer modest efficacy at the cost of significant toxicity.
Response Rates and Quality-of-Life Benefits
Beyond prolonging survival, Daraxonrasib demonstrated meaningful improvements in tumor response.
The confirmed Objective Response Rate (ORR) was nearly three times higher with Daraxonrasib than with chemotherapy. In the RAS G12 population, ORR reached 33.2%, compared with 11.8% for standard treatment. Similar results were observed in the overall study population, where response rates were 31.6% and 11.2%, respectively.
Equally notable were improvements in Patient-Reported Outcomes. Patients receiving Daraxonrasib experienced a significant delay in worsening cancer-related pain and deterioration in overall health status and Quality of Life. Given the substantial symptom burden associated with metastatic pancreatic cancer, these findings underscore the clinical relevance of the survival advantages observed.
The consistency of benefit across multiple efficacy endpoints strengthens the overall therapeutic profile of the agent and suggests that gains in survival are accompanied by meaningful improvements in patient experience.
Favorable Safety Profile Supports Long-Term Use
Safety analyses further distinguished Daraxonrasib from conventional chemotherapy.
Although treatment-related adverse events occurred in nearly all patients, the overall tolerability profile favored the investigational agent. Grade 3 or higher treatment-related adverse events occurred less frequently with Daraxonrasib than with chemotherapy, as did serious treatment-related adverse events, dose reductions, and treatment discontinuations.
The most common toxicities associated with Daraxonrasib were dermatologic and gastrointestinal in nature, including rash, stomatitis, diarrhea, nausea, and vomiting. Most events were low grade and manageable with standard supportive measures and dose modifications.
Importantly, treatment discontinuation due to adverse events occurred in only 1.2% of patients receiving Daraxonrasib, compared with 11.2% among those treated with chemotherapy.
These findings are particularly compelling given the substantially longer median treatment duration achieved with Daraxonrasib, suggesting that prolonged disease control can be attained without a corresponding increase in severe toxicity.
Implications for Clinical Practice
The magnitude of benefit observed in RASolute-302 is noteworthy in the context of metastatic pancreatic cancer, where therapeutic advances have historically been incremental.
Daraxonrasib not only doubled median Overall Survival compared with chemotherapy but also produced consistent benefits across patient subgroups regardless of age, baseline CA19-9 level, prior treatment history, metastatic burden, or RAS mutation status. Such broad activity raises the possibility that targeting the active state of RAS may represent a fundamentally new therapeutic strategy for a disease long considered refractory to precision oncology approaches.
The findings also highlight the potential advantages of multiselective RAS inhibition over mutation-specific approaches. By targeting the activated RAS state rather than a single molecular variant, Daraxonrasib may address the biological heterogeneity that characterizes pancreatic cancer and other RAS-driven malignancies.
Looking Ahead
While RASolute-302 establishes a strong foundation for Daraxonrasib in previously treated metastatic PDAC, additional studies are already exploring its role in earlier disease settings. The ongoing Phase 3 RASolute-303 trial is evaluating Daraxonrasib both as monotherapy and in combination with Gemcitabine plus nab-Paclitaxel in the first-line metastatic setting. Meanwhile, RASolute-304 is investigating the agent as a post-perioperative strategy in patients with resected PDAC. Together, these studies may determine whether broad RAS inhibition can alter the treatment landscape across the continuum of pancreatic cancer care.
Key Takeaway
The Phase 3 RASolute-302 trial represents one of the most significant advances in metastatic pancreatic cancer in recent years. By delivering substantial improvements in Overall Survival, Progression-Free Survival, Response Rates, and Patient-Reported Outcomes, while maintaining a manageable safety profile, Daraxonrasib has emerged as a compelling candidate for a new standard of care in previously treated metastatic PDAC. The results not only validate RAS as a therapeutic target in pancreatic cancer but also signal the arrival of a new generation of broadly active RAS-directed therapies poised to reshape treatment paradigms across oncology.
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. O’Reilly EM, Wainberg ZA, Hendifar AE, et al. for the RASolute 302 Trial Investigators. Published May 31, 2026. DOI: 10.1056/NEJMoa2605555
